Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Sulfonylurea (SU) Monotherapy: A CANVAS Substudy

被引：0

|

作者：

Fulcher, Greg

Matthews, David

Perkovic, Vlado

Mahaffey, Kenneth W.

Weiss, Robert

Rosenstock, Julio

Capuano, George

Desai, Mehul

Shaw, Wayne

Vercruysse, Frank

Meininger, Gary

Neal, Bruce

机构：

来源：

DIABETES | 2013年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1124-P

引用

收藏

页码：A292 / A292

页数：1

相关论文

共 50 条

[21] Effect of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) Who Were, or Were Not, on Antihyperglycemic Agents (AHAs) at Screening
Gonzalez-Galvez, Guillermo
Kim, Kyoung-Ah
Jodar, Esteban
Alba, Maria
Tong, Cindy
Meininger, Gary
DIABETES, 2014, 63 : A280 - A280
[22] Canagliflozin (CANA) Improves Risk Factors of Metabolic Syndrome (MetS) vs. Sitagliptin (SITA) in Patients with Type 2 Diabetes Mellitus (T2DM) and MetS on Background Metformin (MET) plus Sulfonylurea (SU)
Davies, Michael J.
Merton, Katherine
Vijapurkar, Ujjwala
Balis, Dainius
Desai, Mehul
DIABETES, 2016, 65 : A286 - A286
[23] Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program
Mahaffey, Kenneth W.
Ianus, Juliana
Damaraju, C. V.
Neal, Bruce
De Zeeuw, Dick
Fulcher, Greg
Pfeifer, Michael
Matthews, David R.
DIABETES, 2019, 68
[24] Effect of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) Based on Age and Estimated Glomerular Filtration Rate (eGFR)
Gilbert, Richard E.
Weir, Matthew R.
Fioretto, Paola
Law, Gordon
Usiskin, Keith
Meininger, Gary
DIABETES, 2014, 63 : A267 - A267
[25] Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise over 52 weeks
Stenlof, K.
Cefalu, W. T.
Kim, K. -A.
Jodar, E.
Alba, M.
Edwards, R.
Tong, C.
Canovatchel, W.
Meininger, G.
DIABETOLOGIA, 2013, 56 : S374 - S374
[26] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
Erhardt, W.
Bergenheim, K.
Townsend, R.
Puelles, Fernandez de Troconiz J.
McEwan, P.
VALUE IN HEALTH, 2010, 13 (07) : A291 - A292
[27] Canagliflozin (CANA), a Sodium Glucose Co-Transporter 2 Inhibitor, Improves Glycemic Control and Reduces Body Weight in Subjects With Type 2 Diabetes (T2D) Inadequately Controlled With Metformin (MET) and Sulfonylurea (SU)
Wilding, John
Mathieu, Chantal
Vercruysse, Frank
Usiskin, Keith
Deng, Ling
Canovatchel, William
DIABETES, 2012, 61 : A262 - A262
[28] Retrospective study of type 2 diabetes mellitus (T2DM) patients not optimally controlled by metformin monotherapy
He, J.
Neslusan, C.
VALUE IN HEALTH, 2008, 11 (03) : A18 - A18
[29] BAYESIAN NETWORK META-ANALYSIS TO ASSESS THE RELATIVE EFFICACY AND SAFETY OF CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN AND SULPHONYLUREA (MET plus SU)
Pacou, M.
Taieb, V
Abrams, K. R.
Diels, J.
van Sanden, S.
Garg, M.
Schroeder, M.
Kaur, V
Nielsen, A. T. N.
Nuhoho, S.
Neslusan, C.
Hemels, M.
VALUE IN HEALTH, 2013, 16 (07) : A431 - A431
[30] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM
Schroeder, M.
Johansen, P.
Thompson, G.
Willis, M.
Neslusan, C.
VALUE IN HEALTH, 2014, 17 (07) : A344 - A344

← 1 2 3 4 5 →